A long time director and one of the founders of the company, Mr Chen is expected to guide Welichem Biotech through the next crucial stage of development as the company realizes the potential value of its drug candidates in clinical trials.
York Yingping Guo resigned as president and CEO for personal and family reasons.
John Webster, interim chairman of Welichem, said: “Mr Chen has a deep understanding of both the business and scientific components of the company and related international experience in the biotech industry. His commitment and insight will be invaluable.”